Childhood pemphigus treated with gold

Paltzik, R. L.

doi:10.1001/archderm.114.5.768

Cited by 11 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio between boys and girls is the same in each age group except in the 3–5 year group. The youngest female reported is 4 years old 3 and the youngest male only 3 years old 4 …”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Childhood, neonatal, and stillborn pemphigus vulgaris

1999

View full text Add to dashboard Cite

show abstract

“…The ratio between boys and girls is the same in each age group except in the 3–5 year group. The youngest female reported is 4 years old 3 and the youngest male only 3 years old 4 …”

Section: Epidemiologymentioning

confidence: 99%

“…The experience with each of these agents in childhood pemphigus vulgaris is very limited. Under the age of 12 years, only one female has been treated with an adjuvant therapy 3 (Case 1 in Table 4) and only one male 2 (Case 12 in Table 4). Azathioprine has been the most commonly used adjuvant.…”

Section: Treatmentmentioning

confidence: 99%

Childhood, neonatal, and stillborn pemphigus vulgaris

1999

View full text Add to dashboard Cite

show abstract

“…There were 17 boys and 16 girls. The age at the onset of the disease varied from 1.5 to 12 years (mean 8.3 yrs) (8–36). Thirty patients were treated with systemic corticosteroids alone or in combination with ISA for periods that ranged from 0.3 to 11.2 years (mean 4.5 yrs).…”

Section: Resultsmentioning

confidence: 99%

“…Thirty patients were treated with systemic corticosteroids alone or in combination with ISA for periods that ranged from 0.3 to 11.2 years (mean 4.5 yrs). They were followed up for periods ranging from 0.3 to 16 years (mean 5.2 yrs) (8,12–15,17,19,22–36). There were no data provided on the duration of treatment or follow‐up on four patients, but information on the clinical outcome was provided (9–11,16).…”

Section: Resultsmentioning

confidence: 99%

Analysis of Current Therapy and Clinical Outcome in Childhood Pemphigus Vulgaris

Mabrouk

Ahmed

2011

Pediatric Dermatology

View full text Add to dashboard Cite

Pemphigus vulgaris (PV) is a rare, potentially fatal chronic autoimmune disease of the skin and mucous membrane. The objective of this study was to analyze the clinical outcomes and side effects associated with treatment of childhood PV (CPV). A retrospective review of the English language literature was conducted through PUBMED using the words childhood pemphigus vulgaris, and treatment or clinical outcome. Only patients under 12 years of age were included. Thirty-three cases were found in 29 reports. Mean age at onset was 8.3 years (range 1.5-12 yrs). Mucosal involvement (97.0%) was more common than cutaneous involvement (84.8%). Oral mucosa was the most common site of mucosal involvement (93.9%), followed by genital (20.6%), ocular (11.8%), and nasal mucosa (2.9%). Mean duration of therapy was 4.5 years (range 0.6-14.5 yrs), and mean duration of follow-up was 5.2 years (range 0.6-16 yrs). Complete recovery with no further therapy was achieved in 18.2% and partial recovery with minor relapses while on maintenance therapy in 78.8%. One patient died due to infection (3.0%). Serious side effects were present in 60.6%. The most common were cushingoid features (65.0%), growth retardation (50.0%), and infection (50.0%). Two patients who were refractory to systemic corticosteroids and immunosuppressive agents (ISA) had a favorable clinical response to Rituximab. Current therapy for CPV involving the use of long-term systemic corticosteroids in conjunction with ISA results in prolonged immunosuppression, causing systemic infections and growth retardation. Safer and more effective therapies need to be explored.

show abstract

“…However, high-dose and prolonged administration of these agents may result in numerous well-known side effects. Adjuvant steroid-sparing therapies, such as azathioprine [5,6,7,8], methotrexate [6,7], oral gold [9], mycophenolate mofetil [10], intravenous immunoglobulins (IVIg) [11] and dapsone [7,12], have been previously reported as effective in isolated cases of CPV. Therefore, evidence-based guidelines have not been reported for CPV yet.…”

Section: Discussionmentioning

confidence: 99%

Rituximab in Childhood Pemphigus Vulgaris: A Long-Term Follow-Up Case and Review of the Literature

et al. 2010

View full text Add to dashboard Cite

Pemphigus vulgaris is an infrequent but life-threatening autoimmune blistering disease that is rare in the pediatric age. Although the mainstay of therapy for childhood pemphigus vulgaris (CPV) is steroids, adjuvant immunosuppressive drugs are often needed to control the disease. Thus, an important part of CPV morbidity can be related to treatment. We report the youngest CPV patient described in the English literature, an 18-month-old boy, who has been followed up for 16 years. During this period, the patient has received several immunosuppressive therapies with variable response. He has finally achieved a long-lasting and complete remission with rituximab. Successful treatment with rituximab has previously been reported in 6 cases of CPV, in whom rituximab presented a good side effect profile. Our patient has experienced a chronic and severe clinical course with multiple flares eventually developing vegetative lesions. Since he presented refractoriness to multiple therapies, we administered rituximab. The introduction of this drug led to a dramatic clinical response and a long-term clinical remission. Based on the experience of this case and the data reported in the literature, we believe that rituximab may be a safe and efficacious agent for the treatment of severe CPV.

show abstract

Childhood pemphigus treated with gold

Cited by 11 publications

References 0 publications

Childhood, neonatal, and stillborn pemphigus vulgaris

Childhood, neonatal, and stillborn pemphigus vulgaris

Analysis of Current Therapy and Clinical Outcome in Childhood Pemphigus Vulgaris

Rituximab in Childhood Pemphigus Vulgaris: A Long-Term Follow-Up Case and Review of the Literature

Contact Info

Product

Resources

About